Loading
TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.
TST003 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Transcenta Therapeutics (Hangzhou) Co., Ltd., in colorectal cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record. Connects to GREM1.
1.TST003 binds GREM1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TST003" OR ABSTRACT:"TST003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TST003, not a curated reading list.
Shares Transcenta and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.